Skip to main content

Table 1 General characteristics of included studies (about the relationships between CD133 expression and OS or PFS in glioma patients)

From: Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis

First author Year Origin country No. of patients Median/mean age (year) WHO grade Detect method Cut off level Survival end points Follow up period Survival analysis Adjusted variables
Ardebili [10] 2011 Slovenia 24 mean 60 IV QRT-PCR 30 000 (─, 2-ΔΔCt > 30.000) OS NR univariate (KM) NR
Kase [11] 2013 Estonia 42 30–77 IV IHC median OS NR multivariate Radiotherapy dose, Chemotherapy, Karnofsky performance score
Kim [12] 2011 Korea 88 mean 54.9 (13–80) IV IHC 50 % OS mean 13.9 months (1–53) multivariate age, sex, Karnofsky performance scale (KPS) score, extent of removal, chemoradiotherapeutic modality, temozolomide modality, after temozolomide therapy and stem cell marker expression
         PFS    
Melguizo [13] 2012 Italy 75 24–81 IV IHC 25 % OS NR multivariate (KM) NR
         PFS    
Metellus [14] 2011 France 48 mean 60.1 ± 9.2 IV QPCR 1.03 OS Median 18.9 months multivariable Age, extent of surgery, MGMT status (MethyLight)
         PFS    
Shibahara [15] 2013 Japan 112 Media 57 (7–77) IV WB CD133/b-actin ratio = 1 OS Median 25.7 months (3–152) multivariable Ki67 LI (≥35 %), 9p homozygous deletion and 10q loss
Shin [16] 2013 Korea 67 NR IV IHC 50 % OS NR multivariable status
         PFS    
Zeppernik [17] 2008 Germany 48 NR II–III IHC 1 % OS mean 86 months (±39) multivariate age, WHO grade and extent of resection
         PFS    
Dahlrot [18] 2014 Denmark 25 NR II IF median OS Media 12 months multivariate age, performance status (PS) and IDH1 status
         PFS    
Dahlrot [18] 2014 Denmark 26 NR III IF median OS Media 12 months multivariate age, performance status (PS) and IDH1 status
         PFS    
Dahlrot [18] 2014 Denmark 185 NR IV IF median OS Media 12 months multivariate age, performance status (PS) and IDH1 status
         PFS